{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:11:53Z","timestamp":1790187113145,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01248"],"award-info":[{"award-number":["PI21\/01248"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00883"],"award-info":[{"award-number":["PI19\/00883"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PT20\/00127"],"award-info":[{"award-number":["PT20\/00127"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["UMA18-FEDERJA-194"],"award-info":[{"award-number":["UMA18-FEDERJA-194"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PY18-3364"],"award-info":[{"award-number":["PY18-3364"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD21\/00198"],"award-info":[{"award-number":["CD21\/00198"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD20\/00083"],"award-info":[{"award-number":["CD20\/00083"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR21\/00066"],"award-info":[{"award-number":["JR21\/00066"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM21\/00074"],"award-info":[{"award-number":["CM21\/00074"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023731","name":"Consejer\u00eda de Salud y Consumo, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PEMP-0127-2020"],"award-info":[{"award-number":["PEMP-0127-2020"]}],"id":[{"id":"10.13039\/501100023731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023731","name":"Consejer\u00eda de Salud y Consumo, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PI-0310-2018"],"award-info":[{"award-number":["PI-0310-2018"]}],"id":[{"id":"10.13039\/501100023731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023731","name":"Consejer\u00eda de Salud y Consumo, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["POSTDOC_21_00780"],"award-info":[{"award-number":["POSTDOC_21_00780"]}],"id":[{"id":"10.13039\/501100023731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA17112"],"award-info":[{"award-number":["CA17112"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009473","name":"Universidad de M\u00e1laga","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009473","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Idiosyncratic drug-induced liver injury (DILI) associated with drug reactions with eosinophilia and systemic symptoms (DRESS) is poorly characterized among patients of Western countries. We aimed to comprehensively assess the clinical characteristics, outcomes, and causative agents in a prospective, well-vetted cohort of DILI patients with DRESS (DILI-DRESS). We identified 53 DILI-DRESS cases from the Spanish DILI Registry and the Latin American DILI Network. For comparison purposes, we defined a group of DILI patients (n\u2009=\u2009881). DILI-DRESS cases were younger (47 vs. 53\u00a0years, respectively; p\u2009=\u20090.042) and presented more frequently with cholestatic\/mixed damage (p\u2009=\u20090.018). Most DILI-DRESS patients showed moderate liver injury, 13% developed severe damage, and only one patient (with hepatocellular injury due to anti-tuberculosis drugs) progressed to acute liver failure and died. DILI-DRESS cases showed a distinctive causative drug pattern compared to DILI cases. The most frequent drugs were carbamazepine (13%), anti-tuberculosis drugs (13%), amoxicillin-clavulanate (11%), and allopurinol and lamotrigine (7.6% each). Among all cases of DILI due to allopurinol and lamotrigine, 67% presented with a DILI-DRESS phenotype, respectively. Higher total bilirubin (TBL) levels at DILI recognition (odds ratio [OR] 1.23; 95% confidence interval [CI] 1.04\u20131.45) and absence of eosinophilia (OR 8.77; 95% CI 1.11\u201369.20) increased the risk for developing a severe-fatal injury in DILI-DRESS patients. DILI-DRESS patients have a more frequent cholestasis\/mixed pattern of injury at presentation, with antiepileptics as distinctive causative drug class. Most of the lamotrigine and allopurinol cases present with this phenotype. Higher TBL levels and absence of eosinophilia at DILI recognition are markers of poor outcomes.<\/jats:p>","DOI":"10.1007\/s00204-023-03630-0","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T09:02:41Z","timestamp":1701766961000},"page":"303-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries"],"prefix":"10.1007","volume":"98","author":[{"given":"Inmaculada","family":"Medina-C\u00e1liz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Sanabria-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Villanueva-Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauryna","family":"Auk\u0161tikaln\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Robles-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Pinazo-Bandera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Garc\u00eda-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Bessone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelia","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymundo","family":"Paran\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-4896","authenticated-orcid":false,"given":"M. Isabel","family":"Lucena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal J.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Alvarez-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"issue":"6","key":"3630_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ et al (2011) Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 89(6):806\u2013815. https:\/\/doi.org\/10.1038\/clpt.2011.58","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3630_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bjornsson ES et al (2019) Drug-induced liver injury. Nat Rev Dis Primers 5(1):58. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3630_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/ijms17030313","volume":"17","author":"F Bessone","year":"2016","unstructured":"Bessone F, Hernandez N, Lucena MI, Andrade RJ (2016) The Latin American DILI Registry experience: a successful ongoing collaborative strategic initiative. Int J Mol Sci 17(3):313. https:\/\/doi.org\/10.3390\/ijms17030313","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3630_CR4","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/j.1365-2036.2007.03330.x","volume":"25","author":"E Bjornsson","year":"2007","unstructured":"Bjornsson E, Kalaitzakis E, Olsson R (2007) The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 25(12):1411\u20131421. https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03330.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"3630_CR5","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1016\/j.jaip.2021.05.008","volume":"9","author":"SB Bluestein","year":"2021","unstructured":"Bluestein SB, Yu R, Stone C Jr, Phillips EJ (2021) Reporting of drug reaction with eosinophilia and systemic symptoms from 2002 to 2019 in the US food and drug administration adverse event reporting system. J Allergy Clin Immunol Pract 9(8):3208-3211 e1. https:\/\/doi.org\/10.1016\/j.jaip.2021.05.008","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"3630_CR6","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R et al (2015) Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 148(7):1340-1352 e7. https:\/\/doi.org\/10.1053\/j.gastro.2015.03.006","journal-title":"Gastroenterology"},{"issue":"12","key":"3630_CR7","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1001\/archdermatol.2010.198","volume":"146","author":"YC Chen","year":"2010","unstructured":"Chen YC, Chiu HC, Chu CY (2010) Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 146(12):1373\u20131379. https:\/\/doi.org\/10.1001\/archdermatol.2010.198","journal-title":"Arch Dermatol"},{"issue":"5","key":"3630_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jama.2014.7859","volume":"312","author":"WH Chung","year":"2014","unstructured":"Chung WH, Chang WC, Lee YS et al (2014) Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 312(5):525\u2013534. https:\/\/doi.org\/10.1001\/jama.2014.7859","journal-title":"JAMA"},{"issue":"6","key":"3630_CR9","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/cpt.2423","volume":"110","author":"A Cueto-Sanchez","year":"2021","unstructured":"Cueto-Sanchez A, Niu H, Del Campo-Herrera E et al (2021) Lymphocyte profile and immune checkpoint expression in drug-induced liver injury: an immunophenotyping study. Clin Pharmacol Ther 110(6):1604\u20131612. https:\/\/doi.org\/10.1002\/cpt.2423","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"3630_CR10","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46(11):1323\u20131330. https:\/\/doi.org\/10.1016\/0895-4356(93)90101-6","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"3630_CR11","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.14309\/ajg.0000000000001913","volume":"117","author":"H Devarbhavi","year":"2022","unstructured":"Devarbhavi H, Kurien SS, Raj S et al (2022) Idiosyncratic drug-induced liver injury associated with and without drug reaction with eosinophilia and systemic symptoms. Am J Gastroenterol 117(10):1709\u20131713. https:\/\/doi.org\/10.14309\/ajg.0000000000001913","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"3630_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/imj.13734","volume":"48","author":"WC Fang","year":"2018","unstructured":"Fang WC, Adler NR, Graudins LV et al (2018) Drug-induced liver injury is frequently associated with severe cutaneous adverse drug reactions: experience from two Australian tertiary hospitals. Intern Med J 48(5):549\u2013555. https:\/\/doi.org\/10.1111\/imj.13734","journal-title":"Intern Med J"},{"issue":"5","key":"3630_CR13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1053\/j.gastro.2019.07.006","volume":"157","author":"M Ghabril","year":"2019","unstructured":"Ghabril M, Gu J, Yoder L et al (2019) Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury. Gastroenterology 157(5):1245-1252 e3. https:\/\/doi.org\/10.1053\/j.gastro.2019.07.006","journal-title":"Gastroenterology"},{"issue":"11","key":"3630_CR14","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1111\/liv.14990","volume":"41","author":"YS Huang","year":"2021","unstructured":"Huang YS, Wu CY, Chang TT et al (2021) Drug-induced liver injury associated with severe cutaneous adverse drug reactions: a nationwide study in Taiwan. Liver Int 41(11):2671\u20132680. https:\/\/doi.org\/10.1111\/liv.14990","journal-title":"Liver Int"},{"issue":"5","key":"3630_CR15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L et al (2013) Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 169(5):1071\u20131080. https:\/\/doi.org\/10.1111\/bjd.12501","journal-title":"Br J Dermatol"},{"issue":"3","key":"3630_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4168\/aair.2014.6.3.216","volume":"6","author":"DH Kim","year":"2014","unstructured":"Kim DH, Koh YI (2014) Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome. Allergy Asthma Immunol Res 6(3):216\u2013221. https:\/\/doi.org\/10.4168\/aair.2014.6.3.216","journal-title":"Allergy Asthma Immunol Res"},{"issue":"3","key":"3630_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jaad.2013.03.024","volume":"69","author":"T Lee","year":"2013","unstructured":"Lee T, Lee YS, Yoon SY et al (2013) Characteristics of liver injury in drug-induced systemic hypersensitivity reactions. J Am Acad Dermatol 69(3):407\u2013415. https:\/\/doi.org\/10.1016\/j.jaad.2013.03.024","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"3630_CR18","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1111\/jdv.18100","volume":"36","author":"JW Lee","year":"2022","unstructured":"Lee JW, Lee SR, Kim MJ et al (2022) Skin manifestations and clinical features of drug reaction with eosinophilia and systemic symptoms: a retrospective multicentre study of 125 patients. J Eur Acad Dermatol Venereol 36(9):1584\u20131592. https:\/\/doi.org\/10.1111\/jdv.18100","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"3630_CR19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaad.2015.02.1130","volume":"72","author":"IC Lin","year":"2015","unstructured":"Lin IC, Yang HC, Strong C et al (2015) Liver injury in patients with DRESS: a clinical study of 72 cases. J Am Acad Dermatol 72(6):984\u2013991. https:\/\/doi.org\/10.1016\/j.jaad.2015.02.1130","journal-title":"J Am Acad Dermatol"},{"issue":"31","key":"3630_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016717","volume":"98","author":"Z Ma","year":"2019","unstructured":"Ma Z, Wang X, Yin P et al (2019) Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury. Medicine (baltimore) 98(31):e16717. https:\/\/doi.org\/10.1097\/MD.0000000000016717","journal-title":"Medicine (baltimore)"},{"issue":"1","key":"3630_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jhep.2008.03.017","volume":"49","author":"K Pachkoria","year":"2008","unstructured":"Pachkoria K, Lucena MI, Crespo E et al (2008) Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol 49(1):107\u2013114. https:\/\/doi.org\/10.1016\/j.jhep.2008.03.017","journal-title":"J Hepatol"},{"issue":"2","key":"3630_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/j.1365-2133.2006.07284.x","volume":"155","author":"H Peyri\u00e8re","year":"2006","unstructured":"Peyri\u00e8re H, Dereure O, Breton H et al (2006) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 155(2):422\u2013428. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07284.x","journal-title":"Br J Dermatol"},{"issue":"1","key":"3630_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","volume":"147","author":"M Robles-Diaz","year":"2014","unstructured":"Robles-Diaz M, Lucena MI, Kaplowitz N et al (2014) Use of Hy\u2019s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 147(1):109-118 e5. https:\/\/doi.org\/10.1053\/j.gastro.2014.03.050","journal-title":"Gastroenterology"},{"issue":"36","key":"3630_CR24","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.2174\/1381612825666191107161912","volume":"25","author":"J Sanabria-Cabrera","year":"2019","unstructured":"Sanabria-Cabrera J, Medina-Caliz I, Stankeviciute S et al (2019) Drug-induced liver injury associated with severe cutaneous hypersensitivity reactions: a complex entity in need of a multidisciplinary approach. Curr Pharm Des 25(36):3855\u20133871. https:\/\/doi.org\/10.2174\/1381612825666191107161912","journal-title":"Curr Pharm Des"},{"issue":"6","key":"3630_CR25","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1172\/JCI113798","volume":"82","author":"NH Shear","year":"1988","unstructured":"Shear NH, Spielberg SP (1988) Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 82(6):1826\u20131832. https:\/\/doi.org\/10.1172\/JCI113798","journal-title":"J Clin Invest"},{"issue":"11","key":"3630_CR26","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1111\/jdv.13212","volume":"29","author":"F Skowron","year":"2015","unstructured":"Skowron F, Bensaid B, Balme B et al (2015) Drug reaction with eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases. J Eur Acad Dermatol Venereol 29(11):2199\u20132205. https:\/\/doi.org\/10.1111\/jdv.13212","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"3630_CR27","first-page":"386","volume":"217","author":"SP Spielberg","year":"1981","unstructured":"Spielberg SP, Gordon GB, Blake DA, Mellits ED, Bross DS (1981) Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther 217(2):386\u2013389","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3630_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jhep.2021.01.029","volume":"75","author":"C Stephens","year":"2021","unstructured":"Stephens C, Robles-Diaz M, Medina-Caliz I et al (2021) Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. J Hepatol 75(1):86\u201397. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.029","journal-title":"J Hepatol"},{"issue":"5","key":"3630_CR29","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/biomedicines10050999","volume":"10","author":"H Stirton","year":"2022","unstructured":"Stirton H, Shear NH, Dodiuk-Gad RP (2022) Drug reaction with eosinophilia and systemic symptoms (DReSS)\/drug-induced hypersensitivity syndrome (DiHS)-readdressing the DReSS. Biomedicines 10(5):999. https:\/\/doi.org\/10.3390\/biomedicines10050999","journal-title":"Biomedicines"},{"issue":"12","key":"3630_CR30","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3390\/metabo11120852","volume":"11","author":"Z Xie","year":"2021","unstructured":"Xie Z, Zhang L, Chen E et al (2021) Targeted metabolomics analysis of bile acids in patients with idiosyncratic drug-induced liver injury. Metabolites 11(12):852. https:\/\/doi.org\/10.3390\/metabo11120852","journal-title":"Metabolites"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-023-03630-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-023-03630-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-023-03630-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T14:03:24Z","timestamp":1704463404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-023-03630-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3630"],"URL":"https:\/\/doi.org\/10.1007\/s00204-023-03630-0","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been approved by the appropriate local ethics committees and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}